We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
BioMarin Pharmaceutical (BMRN) Just Flashed Golden Cross Signal: Do You Buy?
Read MoreHide Full Article
BioMarin Pharmaceutical Inc. (BMRN - Free Report) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, BMRN's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross."
A golden cross is a technical chart pattern that can signify a potential bullish breakout. It's formed from a crossover involving a security's short-term moving average breaking above a longer-term moving average, with the most common moving averages being the 50-day and the 200-day, since bigger time periods tend to form stronger breakouts.
Golden crosses have three key stages that investors look out for. It starts with a downtrend in a stock's price that eventually bottoms out, followed by the stock's shorter moving average crossing over its longer moving average and triggering a trend reversal. The final stage is when a stock continues the upward climb to higher prices.
A golden cross contrasts with a death cross, another widely-followed chart pattern that suggests bearish momentum could be on the horizon.
BMRN has rallied 22.3% over the past four weeks, and the company is a #3 (Hold) on the Zacks Rank at the moment. This combination indicates BMRN could be poised for a breakout.
The bullish case solidifies once investors consider BMRN's positive earnings outlook. For the current quarter, no earnings estimate has been cut compared to 7 revisions higher in the past 60 days. The Zacks Consensus Estimate has increased too.
Investors should think about putting BMRN on their watchlist given the ultra-important technical indicator and positive move in earnings estimates.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
BioMarin Pharmaceutical (BMRN) Just Flashed Golden Cross Signal: Do You Buy?
BioMarin Pharmaceutical Inc. (BMRN - Free Report) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, BMRN's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross."
A golden cross is a technical chart pattern that can signify a potential bullish breakout. It's formed from a crossover involving a security's short-term moving average breaking above a longer-term moving average, with the most common moving averages being the 50-day and the 200-day, since bigger time periods tend to form stronger breakouts.
Golden crosses have three key stages that investors look out for. It starts with a downtrend in a stock's price that eventually bottoms out, followed by the stock's shorter moving average crossing over its longer moving average and triggering a trend reversal. The final stage is when a stock continues the upward climb to higher prices.
A golden cross contrasts with a death cross, another widely-followed chart pattern that suggests bearish momentum could be on the horizon.
BMRN has rallied 22.3% over the past four weeks, and the company is a #3 (Hold) on the Zacks Rank at the moment. This combination indicates BMRN could be poised for a breakout.
The bullish case solidifies once investors consider BMRN's positive earnings outlook. For the current quarter, no earnings estimate has been cut compared to 7 revisions higher in the past 60 days. The Zacks Consensus Estimate has increased too.
Investors should think about putting BMRN on their watchlist given the ultra-important technical indicator and positive move in earnings estimates.